Fezolinetant,a non-hormonal treatment for perimenopausal vasomotor symptoms
Fezolinetant(tradename:VeozahTM)is the first FDA-approved selective neurokinin 3 receptor(NK3R)antagonist for the treatment of perimenopausal vasomotor symptoms(VMS).Compared with traditional hormone therapy,fezolinetant reduced the risk of cardiovascular adverse events and breast cancer.Clinical studies have demonstrated that fezolinetant can significantly reduce the frequency and severity of moderate-to-severe VMS with good safety.In this article,the mechanism of action,pharmacokinetics,pharmacodynamics,clinical evaluation,safety,and drug interactions of fezolinetant are reviewed.
NETL
NSTL
万方数据
